{"id":456307,"date":"2021-03-11T16:08:12","date_gmt":"2021-03-11T21:08:12","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=456307"},"modified":"2021-03-11T16:08:12","modified_gmt":"2021-03-11T21:08:12","slug":"lumos-pharma-to-participate-in-march-2021-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/","title":{"rendered":"Lumos Pharma to Participate in March 2021 Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">AUSTIN, Texas, March  11, 2021  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CtbPdyd6NDk3WRzH0afrApHH_D7n1Xs1KJWofjsDOwIVKgtCqmoUM1BkcCk8IEkIWo0wcpLkECC8FUBU_VhHYaDuhfQFGXqGmkvaWG4VsuA=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Lumos Pharma, Inc.<\/a>\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences:<\/p>\n<p align=\"justify\">\n        <strong>H.C. Wainwright Global Life Sciences Conference<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:9pt;text-align:justify\">March 10, 2021 \u2013 Pre-recorded presentation available for download<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Oppenheimer 31<\/strong><br \/>\n        <sup><br \/>\n          <strong>st<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Healthcare Conference<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:9pt;text-align:justify\">March 17, 2021 \u2013 Presentation 9:20 \u2013 9:50 AM ET<\/li>\n<li style=\"margin-bottom:9pt;text-align:justify\">March 17, 2021 \u2013 One-on-One Meetings throughout the day<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>33<\/strong><br \/>\n        <sup><br \/>\n          <strong>rd<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> Annual Roth Conference <\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:9pt;text-align:justify\">March 15, 2021 \u2013 One-on-One Meetings throughout the day<\/li>\n<li style=\"margin-bottom:9pt;text-align:justify\">March 17, 2021 \u2013 Presentation 10:00 \u2013 10:25 AM ET<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Inaugural Emerging Growth Conference presented by M-Vest LLC and Maxim Group LLC<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:9pt;text-align:justify\">March 17-19, 2021 \u2013 Pre-recorded presentation available 9:00 AM &#8211; 5:00 PM ET on <a href=\"https:\/\/www.m-vest.com\/events\/2021-emerging-growth-virtual-conference\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">M-Vest platform<\/a><\/li>\n<li style=\"margin-bottom:9pt;text-align:justify\">March 23, 2021 \u2013 Pre-recorded presentation available at 9:00 AM ET on Lumos Pharma\u2019s website<\/li>\n<\/ul>\n<p align=\"justify\">Live Lumos Pharma presentations, as well as those available for download, can be found on the Company\u2019s website under \u201c<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=fv2GDsa3Njko8fr6GJ9f8l6bHm2zviSB69eeUE-r8jK67nbHDlbBMHZJMQYboSfnQhvCdj-_5KASky3wyk8la5-DGoGqBi-g4PBwxpYSyVLYq2gG1EUWjf49yJDocb1M-_8USZnAGd-2dVIvCcyBJQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Events &amp; Presentations<\/a>\u201d in the Investors &amp; Media section. Please contact your institutional salesperson or Lumos Pharma Investor Relations to schedule one-on-one meetings with the management team during these conferences or thereafter.<\/p>\n<p align=\"justify\">\n        <strong>About Lumos Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Lumos Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of therapeutics for rare diseases. Lumos Pharma was founded and is led by a management team with longstanding experience in rare disease drug development and received early funding from leading healthcare investors, including Deerfield Management, a fund managed by Blackstone Life Sciences, Roche Venture Fund, New Enterprise Associates (NEA), Sant\u00e9 Ventures, and UCB. Lumos Pharma\u2019s lead therapeutic candidate is LUM-201, an oral growth hormone stimulating small molecule, currently being evaluated in a Phase 2b clinical trial, the OraGrowtH210 Trial, for the treatment of Pediatric Growth Hormone Deficiency (PGHD). If approved by the FDA, LUM-201 would provide an orally administered alternative to daily injections that current PGHD patients endure for many years of treatment. LUM-201 has received Orphan Drug Designation in both the US and EU. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZOX4hEvU8IxVa_2xd3DcINKKPZXBEkD2FobawZi1Jq55nWUGj_GgxoJEjXubB96mQV529Yc7mJZyD46U7Gge-e4RJkWWPSVrIOuSOJLzmOM=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/lumos-pharma.com\/<\/a>.<\/p>\n<p>Investor &amp; Media Contact:<\/p>\n<p>Lisa Miller<br \/>Lumos Pharma Investor Relations<br \/>512-792-5454<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-xMawPdbiwxSgcdckjW47Rix0_mOLNXLUIsQRhLupj1SA7AMt8V7h06cFJqLynCucrNFktMI-peu-oV54epdzdsoGg-ZaS1ivPCGrSDvaBY=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@lumos-pharma.com<\/a><\/p>\n<p>Source: Lumos Pharma, Inc.<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/d38e808c-0914-46d2-8133-13d989c5fd7a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences: H.C. Wainwright Global Life Sciences Conference March 10, 2021 \u2013 Pre-recorded presentation available for download Oppenheimer 31 st Annual Healthcare Conference March 17, 2021 \u2013 Presentation 9:20 \u2013 9:50 AM ET March 17, 2021 \u2013 One-on-One Meetings throughout the day 33 rd Annual Roth Conference March 15, 2021 \u2013 One-on-One Meetings throughout the day March 17, 2021 \u2013 Presentation 10:00 \u2013 10:25 AM ET Inaugural Emerging Growth Conference presented by M-Vest LLC and Maxim Group LLC March 17-19, 2021 \u2013 Pre-recorded presentation available 9:00 AM &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Lumos Pharma to Participate in March 2021 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-456307","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences: H.C. Wainwright Global Life Sciences Conference March 10, 2021 \u2013 Pre-recorded presentation available for download Oppenheimer 31 st Annual Healthcare Conference March 17, 2021 \u2013 Presentation 9:20 \u2013 9:50 AM ET March 17, 2021 \u2013 One-on-One Meetings throughout the day 33 rd Annual Roth Conference March 15, 2021 \u2013 One-on-One Meetings throughout the day March 17, 2021 \u2013 Presentation 10:00 \u2013 10:25 AM ET Inaugural Emerging Growth Conference presented by M-Vest LLC and Maxim Group LLC March 17-19, 2021 \u2013 Pre-recorded presentation available 9:00 AM &hellip; Continue reading &quot;Lumos Pharma to Participate in March 2021 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-03-11T21:08:12+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Lumos Pharma to Participate in March 2021 Investor Conferences\",\"datePublished\":\"2021-03-11T21:08:12+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/\"},\"wordCount\":342,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/\",\"name\":\"Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\",\"datePublished\":\"2021-03-11T21:08:12+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/lumos-pharma-to-participate-in-march-2021-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lumos Pharma to Participate in March 2021 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk","og_description":"AUSTIN, Texas, March 11, 2021 (GLOBE NEWSWIRE) &#8212; Lumos Pharma, Inc.\u00a0(NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company is participating in the following March 2021 virtual investor conferences: H.C. Wainwright Global Life Sciences Conference March 10, 2021 \u2013 Pre-recorded presentation available for download Oppenheimer 31 st Annual Healthcare Conference March 17, 2021 \u2013 Presentation 9:20 \u2013 9:50 AM ET March 17, 2021 \u2013 One-on-One Meetings throughout the day 33 rd Annual Roth Conference March 15, 2021 \u2013 One-on-One Meetings throughout the day March 17, 2021 \u2013 Presentation 10:00 \u2013 10:25 AM ET Inaugural Emerging Growth Conference presented by M-Vest LLC and Maxim Group LLC March 17-19, 2021 \u2013 Pre-recorded presentation available 9:00 AM &hellip; Continue reading \"Lumos Pharma to Participate in March 2021 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-03-11T21:08:12+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Lumos Pharma to Participate in March 2021 Investor Conferences","datePublished":"2021-03-11T21:08:12+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/"},"wordCount":342,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/","name":"Lumos Pharma to Participate in March 2021 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=","datePublished":"2021-03-11T21:08:12+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE4ODc4MSM0MDYwNTg2IzIwMTY1Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/lumos-pharma-to-participate-in-march-2021-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Lumos Pharma to Participate in March 2021 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456307","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=456307"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/456307\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=456307"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=456307"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=456307"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}